OB:NANO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers.


Snowflake Analysis

Excellent balance sheet and overvalued.

Share Price & News

How has Nordic Nanovector's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NANO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

NANO

3.3%

NO Biotechs

2.8%

NO Market


1 Year Return

-17.2%

NANO

97.9%

NO Biotechs

-3.5%

NO Market

Return vs Industry: NANO underperformed the Norwegian Biotechs industry which returned 97.9% over the past year.

Return vs Market: NANO underperformed the Norwegian Market which returned -3.5% over the past year.


Shareholder returns

NANOIndustryMarket
7 Day0%3.3%2.8%
30 Day30.1%-1.7%4.7%
90 Day16.3%3.3%14.8%
1 Year-17.2%-17.2%97.9%97.9%-0.5%-3.5%
3 Year-67.0%-67.0%84.8%82.7%13.0%1.1%
5 Year15.4%15.4%64.2%59.3%52.5%22.0%

Price Volatility Vs. Market

How volatile is Nordic Nanovector's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Nordic Nanovector undervalued compared to its fair value and its price relative to the market?

6.14x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NANO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NANO is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: NANO is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NANO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NANO is good value based on its PB Ratio (6.1x) compared to the NO Biotechs industry average (7x).


Next Steps

Future Growth

How is Nordic Nanovector forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NANO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NANO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NANO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if NANO's revenue is forecast to grow faster than the Norwegian market.

High Growth Revenue: Insufficient data to determine if NANO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: NANO is forecast to be unprofitable in 3 years.


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Nordic Nanovector performed over the past 5 years?

-22.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NANO is currently unprofitable.

Growing Profit Margin: NANO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NANO is unprofitable, and losses have increased over the past 5 years at a rate of 22.8% per year.

Accelerating Growth: Unable to compare NANO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NANO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3.1%).


Return on Equity

High ROE: NANO has a negative Return on Equity (-151.06%), as it is currently unprofitable.


Next Steps

Financial Health

How is Nordic Nanovector's financial position?


Financial Position Analysis

Short Term Liabilities: NANO's short term assets (NOK410.7M) exceed its short term liabilities (NOK130.9M).

Long Term Liabilities: NANO's short term assets (NOK410.7M) exceed its long term liabilities (NOK8.1M).


Debt to Equity History and Analysis

Debt Level: NANO is debt free.

Reducing Debt: NANO has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NANO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: NANO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 29.9% each year.


Next Steps

Dividend

What is Nordic Nanovector current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NANO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NANO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NANO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NANO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NANO's dividend in 3 years as they are not forecast to pay a notable one for the Norwegian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Lars Nieba (52 yo)

0.50

Tenure

kr778,000

Compensation

Dr. Lars Nieba, PhD, has been Chief Technology Officer of Nordic Nanovector ASA since December 1, 2019 and serves as its Interim Chief Executive Officer since February 26, 2020. Dr. Nieba possess leadershi ...


CEO Compensation Analysis

Compensation vs Market: Lars's total compensation ($USD87.41K) is below average for companies of similar size in the Norwegian market ($USD467.49K).

Compensation vs Earnings: Insufficient data to compare Lars's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Lars Nieba
Interim CEO & Chief Technology Officer0.50yrkr778.00kno data
Malene Brondberg
Chief Financial Officer0.25yrkr2.93m0.014%
NOK 253.2k
Marco Renoldi
Chief Operating Officer4.17yrskr4.13m0.11%
NOK 2.0m
Jostein Dahle
Chief Scientific Officerno datakr2.28m0.31%
NOK 5.5m
Rosemarie Corrigan
Chief Quality Officer2.67yrskr3.26m0.0037%
NOK 65.2k
Gabriele Elbl
Vice President Global Regulatory Affairsno datakr853.00kno data
Fredrik Haavind
Head of Legal & Compliance1.33yrsno datano data
Maureen Deehan
Head of Corporate Development & Strategy2.17yrsno datano data
Reza Safaei
Head of Medical Affairs3yrsno datano data
Mark Wright
Head of Manufacturing1.58yrsno datano data
Christine Blanc
Chief Medical Officerno datano datano data

1.9yrs

Average Tenure

53.5yo

Average Age

Experienced Management: NANO's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Per Anders Samuelsson
Independent Director5.75yrskr360.00kno data
Jan Egberts
Independent Chairman of the Board1.5yrskr520.00kno data
Mark Kaminski
Member of Scientific Advisory Board & Member of Clinical Advisory Boardno datano datano data
Hilde Steineger
Independent Director5.75yrskr360.00k0.0011%
NOK 20.0k
Stephen Schuster
Member of Scientific Advisory Board5.25yrsno datano data
Timothy Illidge
Chairman of Scientific Advisory Board5.25yrsno datano data
Pier Zinzani
Chairman of Scientific Advisory Board5.25yrsno datano data
Arne Kolstad
Member of Scientific Advisory Board5.25yrsno datano data
Dolores Caballero
Member of Scientific Advisory Board5.25yrsno datano data
Armando Lopez-Guillermo
Member of Scientific Advisory Board5.25yrsno datano data
Francesco D'Amore
Member of Scientific Advisory Board5.25yrsno datano data
Wojciech Jurczak
Member of Scientific Advisory Board5.25yrsno datano data

5.3yrs

Average Tenure

59yo

Average Age

Experienced Board: NANO's board of directors are considered experienced (5.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.


Top Shareholders

Company Information

Nordic Nanovector ASA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Nordic Nanovector ASA
  • Ticker: NANO
  • Exchange: OB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr1.772b
  • Shares outstanding: 66.16m
  • Website: https://www.nordicnanovector.com

Number of Employees


Location

  • Nordic Nanovector ASA
  • Kjelsåsveien 168 B
  • Oslo
  • Oslo
  • 884
  • Norway

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NANOOB (Oslo Bors)YesOrdinary SharesNONOKJul 2014
8NNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2014
0R6YLSE (London Stock Exchange)YesOrdinary SharesGBNOKJul 2014
NANOOBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBNOKJul 2014

Biography

Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for haematological cancers. The company’s lead product candidate is Betalutin, an antibody-radionuclide-conjugat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/15 03:55
End of Day Share Price2020/08/14 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.